IGF-1 (Insulin-Like Growth Factor 1)

Understand

Overview

IGF-1 (insulin-like growth factor 1, somatomedin C) is a peptide produced mainly in the liver in response to stimulation by growth hormone (GH) secreted by the pituitary gland. The test measures total IGF-1 concentration in blood serum and is the primary laboratory tool for assessing the function of the somatotropic axis — the hypothalamus-pituitary-liver system responsible for growth in childhood and protein-fat metabolism throughout life.

The key reason IGF-1, rather than growth hormone itself, is tested in clinical practice lies in the differing biology of the two molecules. GH is secreted by the pituitary in a pulsatile fashion, with short, high pulses occurring mainly during deep nighttime sleep and after intense physical exertion, and between pulses its blood concentration can be low enough that a single, random blood draw during the day can give a falsely low result even in someone with normal pituitary function. IGF-1, on the other hand, produced by the liver in response to averaged, around-the-clock exposure to GH and circulating bound to binding proteins (mainly IGFBP-3), has a much longer half-life and a stable concentration throughout the day — this means a single, random blood draw at any time gives a reliable picture of average somatotropic axis activity over the preceding twelve to several dozen hours, something a single GH measurement simply cannot achieve.

The test is ordered in two opposite clinical contexts. First, in diagnosing growth hormone deficiency — in children with growth disorders and in adults with suspected pituitary insufficiency (e.g., after head trauma, tumors of the hypothalamic-pituitary region, or radiotherapy), where low IGF-1 supports the diagnosis, though it usually needs confirmation with a GH stimulation test. Second, in diagnosing growth hormone excess, primarily acromegaly in adults and gigantism in children, where persistently elevated IGF-1 is one of the core screening criteria and a tool for monitoring treatment effectiveness.

Interpreting the result absolutely requires comparison against age- and sex-specific reference ranges, because physiological IGF-1 concentration changes dramatically over the course of life — it rises sharply during puberty, peaking in late adolescence, and then gradually but steadily declines with age, such that a value considered normal for a thirty-year-old would be clearly low for a teenager at the peak of their pubertal growth spurt, and conversely a value normal for a seventy-year-old would look pathologically low in a young adult. For this reason, an IGF-1 result is almost always reported not as an absolute value but as a standard deviation score (SDS) or percentile relative to a population of the same age and sex.

An important limitation of IGF-1 as a diagnostic tool, emphasized in more recent literature reviews, is its imperfect sensitivity and specificity — in a significant proportion of adults with confirmed, severe growth hormone deficiency, IGF-1 concentration remains within normal range, and conversely, low IGF-1 with normal or even elevated GH secretion has been described in states of peripheral resistance to growth hormone action, malnutrition, or chronic liver disease. For this reason, endocrinology guidelines treat IGF-1 as an auxiliary, screening test which, when the result is borderline or clinically ambiguous, needs to be supplemented with a stimulation test (for suspected deficiency) or a glucose suppression test (for suspected acromegaly), rather than as a standalone, definitive diagnostic criterion.

A number of factors unrelated directly to pituitary function also affect the IGF-1 result — nutritional status (fasting and malnutrition lower IGF-1 independent of GH), liver function (cirrhosis and other chronic liver diseases lower the result, since the liver is the main site of IGF-1 production), uncontrolled diabetes, hypothyroidism, and use of oral estrogens, which lower IGF-1 independent of actual GH secretion. A doctor must account for all these factors before interpreting a borderline result as evidence of somatotropic axis pathology.

On the practical side, the test is drawn from venous blood, usually without a strict fasting requirement, though many labs recommend a standard 8-hour fast for result consistency over time. Unlike growth hormone, IGF-1 doesn't need to be measured at a specific time of day or in a series of measurements — this logistical simplicity, stemming from its stable concentration throughout the day, is exactly what makes it the preferred first-line screening test for somatotropic axis assessment, with the full understanding that a definitive diagnosis of GH deficiency or excess rarely rests on this single parameter alone.